Mengis Capital Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.79M | Sell |
63,588
-625
| -1% | -$16.6K | 0.31% | 81 |
|
|
2025
Q4 | $1.6M | Buy |
64,213
+7,056
| +12% | +$178K | 0.28% | 88 |
|
|
2025
Q3 | $1.46M | Sell |
57,157
-1,499
| -3% | -$37K | 0.29% | 88 |
|
|
2025
Q2 | $1.42M | Sell |
58,656
-1
| -0% | -$23 | 0.3% | 89 |
|
|
2025
Q1 | $1.49M | Sell |
58,657
-6,254
| -10% | -$164K | 0.31% | 86 |
|
|
2024
Q4 | $1.72M | Sell |
64,911
-600
| -0.9% | -$16.3K | 0.35% | 75 |
|
|
2024
Q3 | $1.9M | Sell |
65,511
-4,002
| -6% | -$117K | 0.37% | 72 |
|
|
2024
Q2 | $1.94M | Sell |
69,513
-7,986
| -10% | -$220K | 0.39% | 69 |
|
|
2024
Q1 | $2.15M | Buy |
77,499
+13,849
| +22% | +$384K | 0.33% | 69 |
|
|
2023
Q4 | $1.83M | Buy |
63,650
+550
| +0.9% | +$16.6K | 0.34% | 67 |
|
|
2023
Q3 | $2.09M | Sell |
63,100
-701
| -1% | -$24.8K | 0.44% | 59 |
|
|
2023
Q2 | $2.34M | Sell |
63,801
-800
| -1% | -$31.1K | 0.47% | 56 |
|
|
2023
Q1 | $2.64M | Buy |
64,601
+9
| +0% | +$389 | 0.56% | 52 |
|
|
2022
Q4 | $3.31M | Sell |
64,592
-145
| -0.2% | -$6.95K | 0.72% | 40 |
|
|
2022
Q3 | $2.83M | Sell |
64,737
-3,995
| -6% | -$194K | 0.67% | 47 |
|
|
2022
Q2 | $3.6M | Sell |
68,732
-396
| -0.6% | -$20.2K | 0.79% | 35 |
|
|
2022
Q1 | $3.58M | Sell |
69,128
-265
| -0.4% | -$13.8K | 0.69% | 42 |
|
|
2021
Q4 | $4.1M | Sell |
69,393
-4,847
| -7% | -$240K | 0.77% | 35 |
|
|
2021
Q3 | $3.19M | Buy |
74,240
+15
| +0% | +$665 | 0.67% | 42 |
|
|
2021
Q2 | $2.91M | Sell |
74,225
-3,029
| -4% | -$118K | 0.6% | 44 |
|
|
2021
Q1 | $2.8M | Sell |
77,254
-722
| -0.9% | -$25.6K | 0.62% | 45 |
|
|
2020
Q4 | $2.87M | Sell |
77,976
-275
| -0.4% | -$10.1K | 0.7% | 39 |
|
|
2020
Q3 | $2.72M | Sell |
78,251
-1,007
| -1% | -$35.3K | 0.75% | 37 |
|
|
2020
Q2 | $2.46M | Sell |
79,258
-548
| -0.7% | -$18.6K | 0.73% | 38 |
|
|
2020
Q1 | $2.47M | Sell |
79,806
-468
| -0.6% | -$15.9K | 0.84% | 34 |
|
|
2019
Q4 | $2.98M | Sell |
80,274
-996
| -1% | -$35.5K | 0.82% | 36 |
|
|
2019
Q3 | $2.77M | Buy |
81,270
+944
| +1% | +$34.3K | 0.83% | 33 |
|
|
2019
Q2 | $3.3M | Buy |
80,326
+47,388
| +144% | +$1.88M | 1.01% | 28 |
|
|
2019
Q1 | $1.33M | Sell |
32,938
-4,633
| -12% | -$186K | 0.74% | 45 |
|
|
2018
Q4 | $1.55M | Sell |
37,571
-5,160
| -12% | -$214K | 0.99% | 33 |
|
|
2018
Q3 | $1.79M | Sell |
42,731
-673
| -2% | -$25.9K | 0.98% | 30 |
|
|
2018
Q2 | $1.49M | Sell |
43,404
-2,714
| -6% | -$92.7K | 0.88% | 35 |
|
|
2018
Q1 | $1.55M | Buy |
46,118
+4
| +0% | +$138 | 0.93% | 33 |
|
|
2017
Q4 | $1.58M | Buy |
46,114
+352
| +0.8% | +$12K | 0.96% | 30 |
|
|
2017
Q3 | $1.55M | Sell |
45,762
-2,213
| -5% | -$71.1K | 1.04% | 28 |
|
|
2017
Q2 | $1.53M | Sell |
47,975
-316
| -0.7% | -$9.96K | 1.08% | 28 |
|
|
2017
Q1 | $1.57M | Sell |
48,291
-264
| -0.5% | -$8.32K | 1.15% | 28 |
|
|
2016
Q4 | $1.5M | Buy |
48,555
+4,216
| +10% | +$129K | 1.19% | 30 |
|
|
2016
Q3 | $1.42M | Sell |
44,339
-1,581
| -3% | -$52.9K | 1.19% | 31 |
|
|
2016
Q2 | $1.53M | Sell |
45,920
-210
| -0.5% | -$6.7K | 1.35% | 28 |
|
|
2016
Q1 | $1.3M | Buy |
46,130
+758
| +2% | +$21.7K | 1.2% | 29 |
|
|
2015
Q4 | $1.39M | Buy |
45,372
+6,277
| +16% | +$197K | 1.21% | 30 |
|
|
2015
Q3 | $1.17M | Buy |
39,095
+7
| +0% | +$224 | 1.09% | 30 |
|
|
2015
Q2 | $1.24M | Buy |
39,088
+8
| +0% | +$261 | 1.04% | 29 |
|
|
2015
Q1 | $1.29M | Buy |
39,080
+1,587
| +4% | +$50.5K | 1.13% | 25 |
|
|
2014
Q4 | $1.11M | Buy |
+37,493
| New | +$1.08M | 1.07% | 30 |
|
Other funds holding PFE
VCM
VPM
Mengis Capital Management's PFE Position: Q1 2026 in Review
Mengis Capital Management reduced its Pfizer (PFE) stake by 0.97% in Q1 2026, selling an estimated $16.6K and leaving 63,588 shares worth $1.79M. The position accounts for 0.31% of the portfolio, ranked #81.
Mengis Capital Management first reported a position in PFE in Q4 2014 and has held it in 46 quarters since. The position peaked at $4.1M in Q4 2021. 2,934 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- Mengis Capital Management held 63,588 shares of Pfizer worth $1.79M as of Q1 2026.
- Mengis Capital Management sold 625 Pfizer shares in Q1 2026, an estimated $16.6K.
- Pfizer made up 0.31% of Mengis Capital Management's portfolio in Q1 2026, its #81 holding.
- Mengis Capital Management first reported a position in Pfizer in Q4 2014 and has held it in 46 quarters since.
- Mengis Capital Management's Pfizer position peaked at $4.1M in Q4 2021.
- 2,934 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on Mengis Capital Management's 13F filing for Q1 2026, filed 12 May 2026.